PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

被引：96

作者：

Hirsch, Laure ^{[1
]}

Zitvogel, Laurence ^{[2
]}

Eggermont, Alexander ^{[3
]}

Marabelle, Aurelien ^{[1
,2
]}

机构：

[1] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces, Gustave Roussy, F-94805 Villejuif, France

[2] Univ Paris Saclay, INSERM, U1015, Gustave Roussy, F-94805 Villejuif, France

[3] Univ Paris Saclay, Gustave Roussy, F-94805 Villejuif, France

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 120卷 / 01期

关键词：

OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; SAFETY; DOCETAXEL;

D O I：

10.1038/s41416-018-0294-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

引用

页码：3 / 5

页数：3

共 50 条

[41] PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy [J].

Salmaninejad, Arash ;

Valilou, Saeed Farajzadeh ;

Shabgah, Arezoo Gowhari ;

Aslani, Saeed ;

Alimardani, Malihe ;

Pasdar, Alireza ;

Sahebkar, Amirhossein .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (10) :16824-16837

[42] The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer [J].

Qiao, Xin-wei ;

Jiang, Jian ;

Pang, Xin ;

Huang, Mei-chang ;

Tang, Ya-jie ;

Liang, Xin-hua ;

Tang, Ya-ling .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[43] PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers [J].

Xu, Peishuang ;

Hong, Chang ;

Liu, Li ;

Xiao, Lushan .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2025, 1880 (03)

[44] PD-1/PD-L1 inhibitors [J].

Sunshine, Joel ;

Taube, Janis M. .

CURRENT OPINION IN PHARMACOLOGY, 2015, 23 :32-38

[45] Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC [J].

Rosner, Samuel ;

Forde, Patrick M. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) :503-509

[46] PD-1/PD-L1 in disease [J].

Kuol, Nyanbol ;

Stojanovska, Lily ;

Nurgali, Kulmira ;

Apostolopoulos, Vasso .

IMMUNOTHERAPY, 2018, 10 (02) :149-161

[47] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer [J].

Kumar, Rajiv ;

Collins, Dearbhaile ;

Dolly, Saoirse ;

McDonald, Fiona ;

O'Brien, Mary E. R. ;

Yap, Timothy A. .

CURRENT PROBLEMS IN CANCER, 2017, 41 (02) :111-124

[48] Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer [J].

Zhang, Yuedi ;

Cui, Qiulin ;

Xu, Manman ;

Liu, Duo ;

Yao, Shuzhong ;

Chen, Ming .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[49] Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade [J].

Tian, Tian ;

Li, Zhaoming .

FRONTIERS IN ONCOLOGY, 2021, 11

[50] Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials [J].

Zhao, Bin ;

Zhao, Hong ;

Zhao, Jiaxin .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12

← 1 2 3 4 5 →